RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Disrupting Smad3 potentiates immunostimulatory function of NK cells against lung carcinoma by promoting GM-CSF production.
Disrupting Smad3 potentiates immunostimulatory function of NK cells against lung carcinoma by promoting GM-CSF production.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
转化生长因子(TGF-β)通过依赖 Smad3 的信号通路,抑制癌症中 NK 细胞的发育、成熟、细胞因子生成和细胞溶解功能。沉默 Smad3 可显著恢复 NK-92 细胞在富含 TGF-β 的微环境中对癌细胞的细胞毒作用,但其对 NK 细胞免疫调节功能的影响仍不清楚。
本研究发现,Smad3 在 NK 细胞中充当 CSF2(GM-CSF)的转录抑制因子。因此,破坏 Smad3 可显著减轻 TGF-β 对 NK 细胞 GM-CSF 生成的抑制。
此外,在 Smad3 敲除 NK 细胞中沉默 GM-CSF,会显著损害其抗肺癌作用。深入研究表明,NK 来源 GM-CSF 可刺激树突状细胞分化和 M1 巨噬细胞极化,从而增强 T 细胞免疫反应。
同时,NK 来源 GM-CSF 可促进中性粒细胞存活,后者继而促进 NK 细胞终末成熟,进而增强 NK 细胞介导的抗肺癌细胞毒作用。
因此,Smad3 沉默型 NK-92(NK-92-S3KD)具有较强恶性细胞毒性和免疫刺激功能,可增强其他免疫疗法的治疗效果,可能成为具有临床转化价值的辅助免疫疗法。
Through Smad3-dependent signalings, transforming growth factor- (TGF- ) suppresses the development, maturation, cytokine productions and cytolytic functions of NK cells in cancer. Silencing Smad3 remarkably restores the cytotoxicity of NK-92 against cancer in TGF- -rich microenvironment, but its effects on the immunoregulatory functions of NK cells remain obscure. In this study, we identified Smad3 functioned as a transcriptional repressor for CSF2 (GM-CSF) in NK cells.
Therefore, disrupting Smad3 largely mitigated TGF- -mediated suppression on GM-CSF production by NK cells.
Furthermore, silencing GM-CSF in Smad3 knockout NK cells substantially impaired their anti-lung carcinoma effects. In-depth study demonstrated that NK-derived GM-CSF strengthened T cell immune responses by stimulating dendritic cell differentiation and M1 macrophage polarization. Meanwhile, NK-derived GM-CSF promoted the survival of neutrophils, which in turn facilitated the terminal maturation of NK cells, and subsequently boosted NK-cell mediated cytotoxicity against lung carcinoma.
Thus, Smad3-silenced NK-92 (NK-92-S3KD) may serve as a promising immunoadjuvant therapy with clinical translational value given its robust cytotoxicity against malignant cells and immunostimulatory functions to reinforce the therapeutic effects of other immunotherapies.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。